Fig. 1 | British Journal of Cancer

Fig. 1

From: Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study

Fig. 1

The preclinical efficacy of binimetinib and 5-fluorouracil. a Binimetinib demonstrates antitumour activity in biliary tract cancer cell lines. b Synergistic properties of the combination of binimetinib and 5-FU are identified in SNU245, SNU1196, SNU869 and HuCCT1 (CI < 1 at Fa = 0.5). c TS, a 5-FU resistance marker, is upregulated by 5-FU treatment. TS levels induced by 5-FU are downregulated by the addition of binimetinib. Similarly, 5-FU-induced expression of PD-L1 is abrogated by the addition of binimetinib. Actin was included as a loading control. The data are representative of three independent experiments. CI combination index, Fa fraction affected, 5-FU 5-fluorouracil, TS thymidylate synthase, PD-L1 programmed death-ligand 1

Back to article page